\begin{tabular*}{\textwidth}{@{\extracolsep\fill}clllllllllll@{\extracolsep\fill}}
\toprule
&  & \multicolumn{3}{c}{Final Selection (\%)$^1$} & \multicolumn{3}{c}{Allocations (\%)} & &  &  &  \\
\multirow{2}{2em}{Alpha} & \multirow{2}{2em}{Method} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{Toxic~\%$^2$} & \multirow{2}{2em}{DLTs} & \multirow{2}{2em}{Trial Size} & \multirow{2}{2em}{Days}  \\ \\ 
\midrule
\multirow{4}{2em}{0} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.7 & 399\\
 & AIDE-CRM & 50 & 21 & 29 & 28 & 26 & 45 & 26 & 7.2 & 22.8 & 329\\
 & $\alpha$-CRM & 50 & 27 & 23 & 28 & 29 & 43 & 29 & 7.4 & 22.6 & 326\\
 & IPDE-POCRM & 50 & 30 & 20 & 29 & 30 & 41 & 30 & 7.6 & 22.2 & 321\\
\midrule
\multirow{4}{2em}{0.3} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.7 & 398\\
 & AIDE-CRM & 49 & 19 & 32 & 28 & 25 & 46 & 30 & 7.3 & 22.8 & 329\\
 & $\alpha$-CRM & 50 & 24 & 25 & 29 & 27 & 44 & 32 & 7.6 & 22.7 & 326\\
 & IPDE-POCRM & 51 & 26 & 23 & 29 & 29 & 42 & 34 & 7.8 & 22.3 & 321\\
\midrule
\multirow{4}{2em}{0.6} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.8 & 399\\
 & AIDE-CRM & 48 & 16 & 36 & 28 & 24 & 48 & 28 & 7.4 & 22.8 & 329\\
 & $\alpha$-CRM & 51 & 21 & 28 & 29 & 26 & 45 & 30 & 7.7 & 22.6 & 326\\
 & IPDE-POCRM & 52 & 22 & 25 & 29 & 27 & 44 & 32 & 7.9 & 22.2 & 320\\
\midrule
\multirow{4}{2em}{0.9} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.7 & 398\\
 & AIDE-CRM & 48 & 13 & 39 & 28 & 23 & 50 & 31 & 7.6 & 22.9 & 331\\
 & $\alpha$-CRM & 51 & 19 & 30 & 29 & 25 & 46 & 34 & 7.9 & 22.7 & 327\\
 & IPDE-POCRM & 53 & 20 & 28 & 30 & 26 & 44 & 36 & 8.1 & 22.2 & 320\\
\bottomrule
\end{tabular*}
